Company news
Racura Oncology Ltd news in 2023
Racura Oncology Ltd's news releases, calls and decks from 2023, newest first.
December 2023 Preclinical & Clinical Program Update
December 29, 2023
Bonus Options Prospectus
November 21, 2023
Updated Strategy and Investor Presentation
November 21, 2023
Dr Daniel Tillett appointed CEO of Race Oncology
November 21, 2023
RC220 Meets Quality Specifications
November 8, 2023
Impressive Bisantrene Phase 2 AML Clinical Results
November 6, 2023
Trading Halt
November 2, 2023
RC220 Peripheral Infusion Safety Confirmed
October 16, 2023
RC220 Toxicology and Safety Pharmacology Studies Initiated
October 4, 2023
Bisantrene cGMP API Manufacturing Completed at Laurus Labs
September 26, 2023
Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
September 20, 2023
Race Board and Management Team Changes
August 21, 2023
Race Strategic Update August 2023
August 8, 2023
Race Receives Additional $1.66m R&D Tax Refund for FY 2022
July 13, 2023
Race executes agreement with Ardena for GMP manufacturing
July 11, 2023
Race global agreement with City of Hope to access FTO IP
July 9, 2023
H1 2023 Preclinical and Clinical Programs Update
July 6, 2023
Letter to Shareholders
June 15, 2023
Race releases complete cardio-protection data & video
April 13, 2023
Race releases cardioprotection market potential data
April 3, 2023
Race Receives $1.48m R&D Tax Refund for Financial Year 2022
March 27, 2023
Race Leadership Changes
March 23, 2023
Pause in Trading
March 21, 2023
Race Executes Contracts to Commence Breast Cancer Trial
March 12, 2023
New Collaboration to Understand Zantrene Cardioprotection
March 2, 2023
Race Receives Cardioprotection Ethics Trial Approval
January 31, 2023
Decks in 2023
- Race Oncology — Shareholder Meeting (November 2023)
Shareholder meeting · 26 slides · Nov 27, 2023
- Investor Presentation (November 2023)
Investor deck · 51 slides · Nov 22, 2023